Multispecific Immune Engagers: Engineering T Cells, NK Cells and Tumor Recognition Beyond Bispecific Antibodies

Abstract

Multispecific immune engagers represent a transformative advancement in the field of cancer immunotherapy, enabling precise targeting of tumor cells by orchestrating the cytotoxic activities of T cells, natural killer (NK) cells, and other immune effector mechanisms. While bispecific antibodies have demonstrated clinical efficacy in hematologic malignancies and select solid tumors, next-generation multispecific platforms are being engineered to enhance tumor selectivity, overcome immune evasion, and broaden therapeutic scope. This review synthesizes recent evidence on the design, mechanisms, and clinical implications of these complex biologics, focusing on their impact in oncology and the evolving landscape of immune cell redirection strategies.

Introduction

Immunotherapy has revolutionized cancer care, with checkpoint inhibitors, adoptive cell therapies, and monoclonal antibodies markedly improving survival in various malignancies. Among these, the development of bispecific T cell engagers (BiTEs) and related constructs has provided new avenues for harnessing the cytotoxic potential of immune cells. However, limitations such as on-target off-tumor toxicity, resistance mechanisms, and limited efficacy in solid tumors have prompted the evolution of multispecific immune engagers. This review explores the scientific rationale, molecular engineering, and clinical applications of these advanced therapeutics beyond traditional bispecific formats.

Epidemiology / Disease Burden

Cancer remains a leading cause of morbidity and mortality worldwide, accounting for approximately 10 million deaths annually. Despite advances in targeted therapy and immunotherapy, many patients with relapsed/refractory hematologic malignancies or solid tumors have poor prognoses. The unmet need for effective, durable, and safe treatments remains significant, particularly in tumor types characterized by heterogeneous antigen expression, immune evasion, and resistance to conventional therapies. Multispecific immune engagers are being developed to address these gaps and extend the benefits of immunotherapy to broader patient populations.

Pathophysiology

The rationale for multispecific immune engagement is rooted in the complex interplay between tumor cells and the immune system. Tumors employ various mechanisms to evade immune surveillance, including downregulation of antigen presentation, secretion of immunosuppressive cytokines, and recruitment of regulatory cells. By redirecting T cells or NK cells to tumor-associated antigens, multispecific engagers can overcome these barriers. These biologics typically comprise engineered antibody fragments or protein scaffolds that simultaneously bind immune effector cells (e.g., CD3 on T cells, CD16 on NK cells) and one or more tumor antigens, facilitating immune synapse formation and subsequent tumor cell lysis. Some constructs incorporate additional specificity for costimulatory molecules or checkpoint blockade to further potentiate anti-tumor activity.

Risk Factors

Patient selection for multispecific immune engagers hinges on various risk factors, including tumor antigen heterogeneity, immune competence, disease burden, and prior exposure to immunotherapies. Tumors with low or heterogeneous expression of target antigens may exhibit suboptimal responses or develop antigen escape variants. Furthermore, the risk of cytokine release syndrome (CRS), neurotoxicity, and other immune-related adverse events is influenced by tumor burden, immune status, and the specific engager platform. Understanding these risk factors is critical for optimizing patient outcomes and minimizing toxicity.

Clinical Features

Patients receiving multispecific immune engagers may present with a spectrum of clinical manifestations, ranging from rapid tumor regression to immune-related adverse effects. Common toxicities include CRS, characterized by fever, hypotension, and organ dysfunction, as well as neurotoxicity, cytopenias, and infections. The clinical course depends on the engager\'s design, target antigen, dosing regimen, and patient-specific factors. Early identification and management of adverse events are paramount to ensuring safety while maximizing therapeutic benefit.

Diagnosis

Diagnostic evaluation prior to initiation of multispecific immune engager therapy involves comprehensive tumor profiling, including immunohistochemistry or flow cytometry for antigen expression, assessment of immune cell status, and evaluation of comorbidities. Baseline laboratory testing, imaging, and risk stratification are essential to guide therapy selection and monitor for potential complications. Molecular diagnostics also play a pivotal role in identifying actionable targets and predicting response.

Treatment & Management

The administration of multispecific immune engagers requires careful consideration of dosing, route, and supportive care strategies. Step-up dosing protocols, premedication with corticosteroids or antipyretics, and inpatient monitoring are often implemented to mitigate CRS and related toxicities. Management of adverse events relies on established guidelines for immunotherapy complications, including tocilizumab or corticosteroids for severe CRS and supportive measures for neurotoxicity. Multidisciplinary collaboration is essential for optimizing outcomes and addressing complications.

Recent Advances / Emerging Therapies

Recent innovations in the field include trispecific and tetraspecific engagers capable of targeting multiple tumor antigens, co-engaging costimulatory receptors (e.g., CD28, 4-1BB), or combining immune redirection with checkpoint inhibition. Novel platforms such as dual-affinity retargeting molecules (DARTs), tandem diabodies, and NK cell-specific engagers (BiKEs, TriKEs) are under clinical investigation, showing promise in overcoming resistance and expanding the reach of immunotherapy. Early-phase trials in hematologic and solid malignancies have reported durable responses, even in heavily pretreated populations. Advances in protein engineering, linker technology, and half-life extension further enhance the clinical utility of these agents.

Guideline Recommendations

Current expert consensus and professional society guidelines emphasize the importance of patient selection, risk stratification, and adverse event management in multispecific immune engager therapy. Recommendations include baseline evaluation of antigen expression, multidisciplinary monitoring during therapy, and prompt intervention for immune-related toxicities. Ongoing clinical trials and real-world data will inform future updates to guidelines and best practices as these novel agents transition into standard clinical care.

Conclusion

Multispecific immune engagers represent a significant leap forward in immuno-oncology, offering novel mechanisms to overcome tumor resistance, enhance selectivity, and harness the power of the immune system. Ongoing research and clinical experience will refine their role in cancer treatment, with the potential to improve outcomes for patients with refractory or high-risk malignancies. Continued innovation, rigorous clinical evaluation, and adherence to best practices are essential as this field evolves.